PharmaceuticalZai Lab’s Augtyro receives NMPA approval for solid tumours in China DRRA7 days ago01 mins [ad_1] Zai Lab’s Augtyro receives NMPA approval for solid tumours in China Pharmaceutical Business review is using cookies Close [ad_2] Source link Post navigation Previous: Eli Lilly in Talks to Acquire Ventyx Biosciences in USD 1 Billion-Plus DealNext: Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment DRRA1 day ago 0